Chronic obstructive pulmonary disease and cardiovascular risk: Insights from the NAVIGATOR trial

a Brazilian Clinical Research Institute, Sao Paulo, Brazil b Duke Translational MedicineInstitute, Duke University Medical Center, Durham, NC, United States c Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, United States d BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK e Diabetes Trials Unit, Oxford Center for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, UK f San Antonio, TX, United States